0001193125-22-224551.txt : 20220819 0001193125-22-224551.hdr.sgml : 20220819 20220819060600 ACCESSION NUMBER: 0001193125-22-224551 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220819 FILED AS OF DATE: 20220819 DATE AS OF CHANGE: 20220819 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Connect Biopharma Holdings Ltd CENTRAL INDEX KEY: 0001835268 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: E9 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-40212 FILM NUMBER: 221178870 BUSINESS ADDRESS: STREET 1: SCIENCE & TECH PARK, EAST R&D BLDG, 3 FL STREET 2: EAST R&D BUILDING, 3RD FLOOR CITY: 6 BEIJING WEST ROAD, TAICANG STATE: F4 ZIP: 215400 BUSINESS PHONE: 86 512 5357 7866 MAIL ADDRESS: STREET 1: SCIENCE & TECH PARK, EAST R&D BLDG, 3 FL STREET 2: EAST R&D BUILDING, 3RD FLOOR CITY: 6 BEIJING WEST ROAD, TAICANG STATE: F4 ZIP: 215400 6-K 1 d377033d6k.htm 6-K 6-K

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 6-K

 

 

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of August 2022

Commission File Number: 001-40212

 

 

Connect Biopharma Holdings Limited

(Translation of registrant’s name into English)

 

 

12265 El Camino Real, Suite 350

San Diego, CA 92130

(Address of principal executive office)

 

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F  ☒            Form 40-F  ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):  ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):  ☐

 

 

 

INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K

On August 17, 2022, Connect Biopharma Holdings Limited (the “Company”) received written notice from the Listing Qualifications Department of the Nasdaq Stock Market (“Nasdaq”) stating that the Company has regained compliance with the Nasdaq minimum bid price continued listing requirement and the matter is now closed.

The Company was previously notified by Nasdaq on June 16, 2022, that it was not in compliance with the minimum bid price requirement because the Company’s American Depositary Shares (“ADSs”) had failed to maintain a minimum bid price of $1.00 or more for 30 consecutive business days. To regain compliance, the Company’s ADSs were required to maintain a minimum closing bid price of $1.00 or more for at least 10 consecutive trading days, which was achieved on August 16, 2022.

This report on Form 6-K shall be deemed to be incorporated by reference into the registration statements on Form F-3 (Registration No. 333-264340) and Form S-8 (Registration Nos. 333-254524 and 333-266006) of the Company and to be a part thereof from the date on which this report is furnished, to the extent not superseded by documents or reports subsequently filed or furnished.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

Dated: August 19, 2022     CONNECT BIOPHARMA HOLDINGS LIMITED
    By  

/s/ Steven Chan

      Name: Steven Chan
      Title: Chief Financial Officer